Ongoing Investigation into Boston Scientific Corporation (BSX): Contact Levi & Korsinsky About Potential Fraud

Core Insights - Boston Scientific Corporation reported fourth-quarter 2025 results, exceeding analyst expectations for earnings per share and total revenue, but its electrophysiology segment sales fell short of consensus estimates by approximately $43 million [2][5] - The electrophysiology market is rapidly growing, with Boston Scientific's pulsed field ablation technology positioned as a potential alternative to traditional thermal ablation procedures [3] - Following the earnings release, Boston Scientific's shares dropped 17.5%, reaching a 52-week low of $75.50, due to a significant gap between market expectations and the company's internal growth outlook for the electrophysiology segment [5] Company Performance - Boston Scientific's electrophysiology segment reported sales of $890 million, below the consensus estimate of $933 million [2] - The company had previously guided for organic growth of 11% to 13% for Q4 2025, while analysts expected approximately 25% growth [4][5] - The company emphasized strong growth rates in previous quarters, with 94% in Q2 2025 and 63% in Q3 2025 [4] Market Dynamics - The electrophysiology market is one of the fastest-growing areas in cardiovascular medicine, with expectations for global pulsed field ablation penetration to reach 50% by the end of 2025 and approximately 80% by 2028 [3] - Boston Scientific entered this market through the acquisition of Farapulse in 2021 and has made significant investments in manufacturing capacity and physician training programs [3]